VEGFA and lung cancer: PHA665752 in mouse xenografts from small cell (NCI-H441 and A549) and non-small cell (NCI-H441 and A549) lung cancer cell lines(NCI-H69), angiogenic conversion was caused by in of c-Met phosphorylation and angiogenesis at the c-Cbl binding site, due to this, thrombsinin-1 synthesis increased whereas vascular endothelial growth factor production dropped (Crosswell et al. 2009).These investigations indicate the effectiveness of competitive small-molecule ATP inhibitors in selective c-Met targeting, and they propose that PHA665752 could offer a potential tumor therapeutic approach.